Sontuzumab (AS1402), a humanized IgG1κ monoclonal antibody targeting MUC1, exhibits high affinity, with a dissociation constant (Kd) of approximately 1 nM for the extracellular peptide sequence PDTR of MUC1. It is utilized in breast cancer research [1].

Sontuzumab (huHMFG-1; 0-25 μg/mL) 能诱发抗体依赖性细胞毒性（ADCC），作用于ZR-75-1乳腺癌细胞、三种乳腺癌患者的骨髓源性肿瘤细胞系 (KM22、1590、HG15)，以及转染有人类MUC1基因的中国仓鼠卵巢（CHO）细胞。研究表明，不表达人类MUC1的细胞系在Sontuzumab的作用下对ADCC反应不敏感。[1] [2]